By Donna LaVoie
Life science companies, including big and small pharma, biotech and health technology, continue the trend toward partnerships to research, develop and/or commercialize their innovations, allowing companies to enter new markets, continue niche disease research and development and introduce innovations sooner. Adding to the mix are accelerators and venture firms launching new companies into the health science and technology ecosystem.
Even though they are joining forces, and likely have the same end-goal, each of these companies will have a unique, and sometimes competing, set of communications and business goals. They also may have different priorities on stakeholder mix. While it’s easy to default to the needs of the larger company, strategic communications entails finding ways to balance the needs of all parties in the transaction.